文献速递肝病

家庭持续特利加压素输注治疗门静脉高压并发症的真实世界经验

Real-World Experience of Home Continuous Terlipressin Infusion for Complications of Portal Hypertension.
PubMed 文献 · Am J Gastroenterol · 2025-06-11

该纵向队列纳入2013至2023年间接受至少2周家庭持续特利加压素输注(CTI)的102例适合肝移植的失代偿期肝硬化患者,中位MELD-Na评分24,中位治疗84天。与CTI前相比,握力增加2.84 kg、体重降低10.6 kg、穿刺频率减少58%、肌酐中位降低0.61 mg/dL,血清钠无显著变化;36例患者发生49例治疗相关不良事件,84%为中心静脉导管相关,无血管事件、肺水肿或需终止治疗的事件。

要点

  • 家庭CTI与握力增加2.84 kg、体重降低10.6 kg、穿刺频率减少58%及肌酐降低0.61 mg/dL相关。
  • 36例患者共发生49例治疗相关不良事件,其中84%为中心静脉导管相关。
  • 未发生血管事件、肺水肿或需终止治疗的事件。

核心结论

  • 本研究在100例以上经过良好筛选的适合肝移植的失代偿期肝硬化患者真实世界队列中证明家庭CTI的安全性。
  • 研究证实既往发现,即长期CTI与握力增加和穿刺减少相关,并对其已确立的肾功能获益予以补充。
  • 这些数据为进一步开展前瞻性随机试验以研究CTI作为肝移植桥接治疗提供了强有力的临床依据。

研究设计与样本

  • 纵向队列研究,纳入2013年至2023年间接受至少2周家庭CTI治疗门静脉高压并发症的所有患者。
  • 共纳入102例适合肝移植的患者,中位MELD-Na评分为24(四分位距20-29)。
  • 记录CTI前和CTI期间的握力、体重、血清生化及穿刺频率,以及CTI相关不良事件和CTI前与CTI期间的非计划再入院。
  • 随访至肝移植、停止CTI、死亡或统计截止日期。

主要发现

  • 患者接受CTI的中位时间为84天(四分位距58-151天)。
  • 与CTI前相比,握力增加2.84 kg(95%CI 1.89-3.80),体重降低10.6 kg(95%CI -12.70至-8.52),两者均P<0.0001。
  • 穿刺频率减少58%(P=0.006),肌酐中位降低0.61 mg/dL(95%CI -0.87至-0.3)(P<0.001)。
  • 血清钠无显著变化。
  • 在累计12312天中,36例患者记录到49例治疗相关不良事件,其中84%为中心静脉导管相关;无血管事件、肺水肿或需终止治疗的事件。

临床怎么用

  • 作者认为这些数据为进一步开展前瞻性随机试验以研究CTI作为肝移植桥接治疗提供了强有力的临床依据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Home continuous terlipressin infusion (CTI) is an emerging therapy for the treatment of portal hypertensive complications in decompensated cirrhosis. This study presents efficacy and safety data of long-term CTI in a longitudinal cohort. METHODS: All patients treated with at least 2 weeks of home CTI for portal hypertensive complications between 2013 and 2023 were included. Recorded data include handgrip strength (HGS), weight, serum biochemistry, and paracentesis frequency pre-CTI and during CTI. Adverse events related to CTI and unplanned readmissions before and during CTI were recorded. Patients were followed until liver transplantation, CTI cessation, death, or census date. RESULTS: One hundred and two transplant-eligible patients with median Model for End-Stage Liver Disease with sodium 24 (interquartile range 20-29) were treated with CTI for 84 (58-151) days. Compared with pre-CTI, HGS increased by 2.84 kg (95% confidence interval [CI] 1.89-3.80), while body weight reduced by 10.6 kg (95% CI -12.70 to -8.52) (both P < 0.0001). Paracentesis frequency reduced by 58% ( P = 0.006) and median creatinine by 0.61 mg/dL (95% CI -0.87 to -0.3) ( P < 0.001). Serum sodium did not significantly change. Over a cumulative total of 12,312 days, 49 treatment-related adverse events were recorded in 36 patients, 84% of which were central line related. There were no vascular events, episodes of pulmonary edema, or events requiring treatment cessation. DISCUSSION: This study demonstrates the safety of home CTI in a real-world cohort of over 100 well-selected transplant-eligible patients with decompensated cirrhosis. It confirms previous findings that long-term CTI is associated with increased HGS and reduced paracentesis, in addition to its established benefit on renal function. These data provide strong clinical rationale for further prospective randomized trials to investigate the use of CTI as a bridge to liver transplant.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Chapman B, Sinclair M, Majumdar A, et al. Real-World Experience of Home Continuous Terlipressin Infusion for Complications of Portal Hypertension. Am J Gastroenterol. 2025. PMID: 40498117. doi:10.14309/ajg.0000000000003589

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。